An ejection fraction >35% is unconventional to be considered "preserved," so the results of this trial are inconclusive on whether patients with heart failure and ejection fractions usually ...

HEART failure with preserved ejection fraction (HFpEF) is present in 74% of patients with severe isolated secondary tricuspid ...

Therapies are needed for patients with heart failure with mildly reduced or preserved ejection fraction. New research findings on the nonsteroidal mineralocorticoid receptor antagonist finerenone ...

Implantation of the Ventura interatrial shunt, while safe, does not improve clinical outcomes or prognosis in patients with HF and preserved LVEF.

Duke-NUS scientists and their collaborators have discovered a potential new treatment for heart failure with preserved ...

Bayer will present three new prespecified subgroup analyses from the pivotal Phase III FINEARTS-HF cardiovascular outcomes trial investigating KERENDI ...

Although finerenone has kidney protective effects in patients with chronic kidney disease and type 2 diabetes, it does not appear to slow kidney function decline in patients with heart failure with ...

Systolic heart failure happens when the heart pumps at 40% or less of its ejection fraction. Ejection fraction measures how much blood the heart pumps with each contraction or beat. Systolic heart ...

Risk for heart failure events is decreased and health status is improved in patients with HFmrEF and HFpEF receiving finerenone.

led to an 18% reduction in cardiovascular death or worsening heart failure in patients with both mildly reduced and preserved ejection fraction, said AZ. Ejection fraction is a measure of how much ...

The novel investigational weight loss agent HU6 had mixed results specifically targeting obesity-related heart failure with ...

Objective: To provide an overview of heart failure with preserved ejection fraction (HFPEF), as well as its pathophysiology, diagnosis, and clinical evidence regarding its pharmacologic management.